Earnings Surprises

Biggest EPS beats and misses, ranked by post-earnings price reaction. Free data, no paywall.

Q3 2026 Season
60% beat EPS(vs Q2 2026: 60% beat)Avg surprise: +7.0%Avg reaction: -1.0%22% raised guidance5% lowered464/503 S&P 5004,118 reported

Beats and misses reported Nov 18, 2025 – Nov 18, 2026

Biggest EPS Beats25

Ranked by EPS surprise % (highest first). Price reaction = day after report.

#SymbolCompanySectorDateEPS ActualEPS Est.SurprisePrice Reaction
1iRhythm Technologies, Inc.HealthcareNov 5, 2026$0.82↑ Raised$0.02+5190%-32.7%
Quentin Blackford, President and Chief Executive Officer

Our third quarter results reflect the continued strength of our core business. Demand for Zio Monitor remains robust, exceeding our expectations in the quarter, driven by volume growth across care settings and channels.

2BillionToOne, Inc.HealthcareMay 6, 2026$0.34$0.01+3300%+16.3%
3Caris Life Sciences, Inc.HealthcareFeb 26, 2026$0.28$0.01+2700%+10.0%
4Lakefront Biotherapeutics N.V.HealthcareFeb 23, 2026$16.38$1.00+1538%+1.8%
5BioCryst Pharmaceuticals, Inc.HealthcareFeb 26, 2026$1.12$0.07+1500%+15.9%
6Corcept Therapeutics IncorporatedHealthcareJul 29, 2026$0.36$0.02+1381%+25.6%
7Legend Biotech CorporationHealthcareNov 10, 2026$0.14$0.01+1300%-16.0%
8Hinge Health, Inc.HealthcareFeb 10, 2026$0.49$0.04+1125%+20.5%
9ACADIA Pharmaceuticals Inc.HealthcareFeb 25, 2026$1.60$0.14+1068%+0.2%
10Alnylam Pharmaceuticals, Inc.HealthcareOct 29, 2026$16.26$1.66+880%-25.1%
11Cronos Group Inc.HealthcareAug 6, 2026$0.09$0.01+800%+14.0%
Mike Gorenstein, Chairman, President and CEO

Cronos delivered a record second quarter by organically achieving record net revenue, record gross profit and record Adjusted EBITDA, while also reducing our share count. Cronos Israel delivered its tenth consecutive quarter of record net revenue, continuing to secure PEACE NATURALS as the leading cannabis brand in the country. Outside of Israel, our international business also delivered a record net revenue quarter, led by momentum in Germany. In Canada, the Spinach brand continued to gain sign

12iRhythm Technologies, Inc.HealthcareFeb 19, 2026$0.17$0.02+750%-1.9%
13Cronos Group Inc.HealthcareMay 11, 2026$0.04$0.01+700%+9.1%

Cronos delivered record net revenue and gross profit in the first quarter, as we continue to execute against our borderless products strategy and as additional supply from the expansion at Cronos GrowCo fuels our next phase of growth.

14Agilon Health, Inc.HealthcareAug 5, 2026$1.04↑ Raised$0.14+622%-8.4%
Tim O’Rourke, Chief Executive Officer

Our second quarter results exceeded our expectations, demonstrating meaningful progress across agilon's strategic initiatives and reinforcing our confidence in the strength of our Total Care Model.

15STAAR Surgical CompanyHealthcareMay 13, 2026$0.38$0.05+601%+13.6%

STAAR is off to a strong start in 2026, as reflected in our first quarter financial results. We have made meaningful advancements against our core objectives of Revenue Growth and Profit Expansion.

16Centene Corp.HealthcareOct 27, 2026$0.58↑ Raised$0.10+506%+1.0%
Sarah M. London, Chief Executive Officer

Solid underlying fundamentals within our core businesses have powered a faster recovery to our earnings trajectory than previously anticipated,

17CareDx, IncHealthcareFeb 24, 2026$0.12$0.02+503%-1.8%
18Innoviva, Inc.HealthcareFeb 25, 2026$1.94$0.34+471%+0.5%
19Fortrea Holdings Inc.HealthcareMay 5, 2026$0.16— Maintained$0.03+433%+27.7%

We started the year strong, focused on delivering for our clients with excellence and making advances in our strategic journey back to growth and margin expansion.

20AMN Healthcare Services, Inc.HealthcareNov 5, 2026$1.16↓ Lowered$0.23+406%-24.2%
Cary Grace, President and Chief Executive Officer

We are encouraged by the continued growth in nursing and allied staffing. Demand strengthened during the third quarter and through October and our team is delivering for our clients through faster recruiting, automation,

21Alignment Healthcare, Inc.HealthcareApr 30, 2026$0.05↑ Raised$0.01+400%-6.7%
John Kao, founder and CEO

Our first-quarter performance demonstrates that Alignment continues to grow with discipline. We expanded our profitability by executing across sales, clinical operations and cost management, even as the Medicare Advantage environment continues to change.

22Vericel CorporationHealthcareNov 5, 2026$0.27↑ Raised$0.06+371%+20.1%
Nick Colangelo, President and CEO

The Company delivered outstanding financial and business results in the third quarter as we continue to generate top-tier revenue and profit growth as well as significant free cash flow, while also returning capital to shareholders.

23Arcutis Biotherapeutics, Inc.HealthcareFeb 25, 2026$0.13$0.03+333%+5.9%
24Nutex Health, Inc.HealthcareNov 19, 2025$7.76$1.81+329%+43.5%
25AMN Healthcare Services, Inc.HealthcareAug 6, 2026$0.77— Maintained$0.19+308%+9.8%
Cary Grace, President and Chief Executive Officer

We are very pleased with how the AMN team executed for our healthcare professionals and clients in the second quarter. Our strong performance produced year-over-year revenue growth in our travel nurse, international nurse, allied, schools, and search solutions.

IRTC logo1IRTCiRhythm Technologies, Inc.Nov 5, 2026
Mkt Cap$3.1B
EPS Act.$0.82
EPS Est.$0.02
Surprise+5190%
Reaction-32.7%
SectorHealthcare
Quentin Blackford, President and Chief Executive Officer

Our third quarter results reflect the continued strength of our core business. Demand for Zio Monitor remains robust, exceeding our expectations in the quarter, driven by volume growth across care settings and channels.

BLLN logo2BLLNBillionToOne, Inc.May 6, 2026
Mkt Cap$4.2B
EPS Act.$0.34
EPS Est.$0.01
Surprise+3300%
Reaction+16.3%
SectorHealthcare
CAI logo3CAICaris Life Sciences, Inc.Feb 26, 2026
Mkt Cap$5.5B
EPS Act.$0.28
EPS Est.$0.01
Surprise+2700%
Reaction+10.0%
SectorHealthcare
LKFT logo4LKFTLakefront Biotherapeutics N.V.Feb 23, 2026
Mkt Cap$2.2B
EPS Act.$16.38
EPS Est.$1.00
Surprise+1538%
Reaction+1.8%
SectorHealthcare
BCRX logo5BCRXBioCryst Pharmaceuticals, Inc.Feb 26, 2026
Mkt Cap$1.9B
EPS Act.$1.12
EPS Est.$0.07
Surprise+1500%
Reaction+15.9%
SectorHealthcare
CORT logo6CORTCorcept Therapeutics IncorporatedJul 29, 2026
Mkt Cap$7.3B
EPS Act.$0.36
EPS Est.$0.02
Surprise+1381%
Reaction+25.6%
SectorHealthcare
LEGN logo7LEGNLegend Biotech CorporationNov 10, 2026
Mkt Cap$3.0B
EPS Act.$0.14
EPS Est.$0.01
Surprise+1300%
Reaction-16.0%
SectorHealthcare
HNGE logo8HNGEHinge Health, Inc.Feb 10, 2026
Mkt Cap$8.9B
EPS Act.$0.49
EPS Est.$0.04
Surprise+1125%
Reaction+20.5%
SectorHealthcare
ACAD logo9ACADACADIA Pharmaceuticals Inc.Feb 25, 2026
Mkt Cap$3.1B
EPS Act.$1.60
EPS Est.$0.14
Surprise+1068%
Reaction+0.2%
SectorHealthcare
ALNY logo10ALNYAlnylam Pharmaceuticals, Inc.Oct 29, 2026
Mkt Cap$19.9B
EPS Act.$16.26
EPS Est.$1.66
Surprise+880%
Reaction-25.1%
SectorHealthcare
CRON logo11CRONCronos Group Inc.Aug 6, 2026
Mkt Cap$1.2B
EPS Act.$0.09
EPS Est.$0.01
Surprise+800%
Reaction+14.0%
SectorHealthcare
Mike Gorenstein, Chairman, President and CEO

Cronos delivered a record second quarter by organically achieving record net revenue, record gross profit and record Adjusted EBITDA, while also reducing our share count. Cronos Israel delivered its tenth consecutive quarter of record net revenue, continuing to secure PEACE NATURALS as the leading cannabis brand in the country. Outside of Israel, our international business also delivered a record net revenue quarter, led by momentum in Germany. In Canada, the Spinach brand continued to gain sign

IRTC logo12IRTCiRhythm Technologies, Inc.Feb 19, 2026
Mkt Cap$3.1B
EPS Act.$0.17
EPS Est.$0.02
Surprise+750%
Reaction-1.9%
SectorHealthcare
CRON logo13CRONCronos Group Inc.May 11, 2026
Mkt Cap$1.2B
EPS Act.$0.04
EPS Est.$0.01
Surprise+700%
Reaction+9.1%
SectorHealthcare

Cronos delivered record net revenue and gross profit in the first quarter, as we continue to execute against our borderless products strategy and as additional supply from the expansion at Cronos GrowCo fuels our next phase of growth.

AGL logo14AGLAgilon Health, Inc.Aug 5, 2026
Mkt Cap$1.5B
EPS Act.$1.04
EPS Est.$0.14
Surprise+622%
Reaction-8.4%
SectorHealthcare
Tim O’Rourke, Chief Executive Officer

Our second quarter results exceeded our expectations, demonstrating meaningful progress across agilon's strategic initiatives and reinforcing our confidence in the strength of our Total Care Model.

STAA logo15STAASTAAR Surgical CompanyMay 13, 2026
Mkt Cap$1.3B
EPS Act.$0.38
EPS Est.$0.05
Surprise+601%
Reaction+13.6%
SectorHealthcare

STAAR is off to a strong start in 2026, as reflected in our first quarter financial results. We have made meaningful advancements against our core objectives of Revenue Growth and Profit Expansion.

CNC logo16CNCCentene Corp.Oct 27, 2026
Mkt Cap$33.3B
EPS Act.$0.58
EPS Est.$0.10
Surprise+506%
Reaction+1.0%
SectorHealthcare
Sarah M. London, Chief Executive Officer

Solid underlying fundamentals within our core businesses have powered a faster recovery to our earnings trajectory than previously anticipated,

CDNA logo17CDNACareDx, IncFeb 24, 2026
Mkt Cap$3.8B
EPS Act.$0.12
EPS Est.$0.02
Surprise+503%
Reaction-1.8%
SectorHealthcare
INVA logo18INVAInnoviva, Inc.Feb 25, 2026
Mkt Cap$1.4B
EPS Act.$1.94
EPS Est.$0.34
Surprise+471%
Reaction+0.5%
SectorHealthcare
FTRE logo19FTREFortrea Holdings Inc.May 5, 2026
Mkt Cap$1.9B
EPS Act.$0.16
EPS Est.$0.03
Surprise+433%
Reaction+27.7%
SectorHealthcare

We started the year strong, focused on delivering for our clients with excellence and making advances in our strategic journey back to growth and margin expansion.

AMN logo20AMNAMN Healthcare Services, Inc.Nov 5, 2026
Mkt Cap$1.5B
EPS Act.$1.16
EPS Est.$0.23
Surprise+406%
Reaction-24.2%
SectorHealthcare
Cary Grace, President and Chief Executive Officer

We are encouraged by the continued growth in nursing and allied staffing. Demand strengthened during the third quarter and through October and our team is delivering for our clients through faster recruiting, automation,

ALHC logo21ALHCAlignment Healthcare, Inc.Apr 30, 2026
Mkt Cap$1.4B
EPS Act.$0.05
EPS Est.$0.01
Surprise+400%
Reaction-6.7%
SectorHealthcare
John Kao, founder and CEO

Our first-quarter performance demonstrates that Alignment continues to grow with discipline. We expanded our profitability by executing across sales, clinical operations and cost management, even as the Medicare Advantage environment continues to change.

VCEL logo22VCELVericel CorporationNov 5, 2026
Mkt Cap$3.0B
EPS Act.$0.27
EPS Est.$0.06
Surprise+371%
Reaction+20.1%
SectorHealthcare
Nick Colangelo, President and CEO

The Company delivered outstanding financial and business results in the third quarter as we continue to generate top-tier revenue and profit growth as well as significant free cash flow, while also returning capital to shareholders.

ARQT logo23ARQTArcutis Biotherapeutics, Inc.Feb 25, 2026
Mkt Cap$3.5B
EPS Act.$0.13
EPS Est.$0.03
Surprise+333%
Reaction+5.9%
SectorHealthcare
NUTX logo24NUTXNutex Health, Inc.Nov 19, 2025
Mkt Cap$1.2B
EPS Act.$7.76
EPS Est.$1.81
Surprise+329%
Reaction+43.5%
SectorHealthcare
AMN logo25AMNAMN Healthcare Services, Inc.Aug 6, 2026
Mkt Cap$1.5B
EPS Act.$0.77
EPS Est.$0.19
Surprise+308%
Reaction+9.8%
SectorHealthcare
Cary Grace, President and Chief Executive Officer

We are very pleased with how the AMN team executed for our healthcare professionals and clients in the second quarter. Our strong performance produced year-over-year revenue growth in our travel nurse, international nurse, allied, schools, and search solutions.

Biggest EPS Misses25

Ranked by EPS miss % (worst first). Price reaction = day after report.

#SymbolCompanySectorDateEPS ActualEPS Est.SurprisePrice Reaction
1Ascentage Pharma Group InternationalHealthcareAug 20, 2026-$1.28$0.02-7850%-5.7%
2Madrigal Pharmaceuticals, Inc.HealthcareFeb 19, 2026-$2.57$0.04-6525%-11.5%
3BioCryst Pharmaceuticals, Inc.HealthcareMay 6, 2026-$2.98$0.06-5067%-1.4%
4Hims & Hers Health, Inc.HealthcareMay 11, 2026-$0.40↑ Raised$0.03-1675%-11.5%

2026 is a defining year for Hims & Hers. We're not just growing, we're pulling away from the field on our path to becoming the world's largest consumer health platform.

5Xeris Biopharma Holdings, Inc.HealthcareAug 6, 2026-$0.18$0.01-1588%-2.2%
6Molina Healthcare, Inc.HealthcareFeb 5, 2026-$2.75$0.43-740%-26.0%
7Mirum Pharmaceuticals, Inc.HealthcareFeb 25, 2026-$0.11$0.02-650%-14.2%
8AdaptHealth Corp.HealthcareMay 5, 2026-$0.06↑ Raised$0.01-580%-12.4%

The opening months of 2026 have set the stage for what will be a defining year for AdaptHealth. We completed the largest de novo expansion in the history of the home medical equipment industry, delivering revenue well ahead of our first quarter guidance.

9PTC Therapeutics, Inc.HealthcareOct 29, 2026-$0.62↑ Raised$0.14-532%-7.0%
Matthew B. Klein, M.D., Chief Executive Officer

We delivered another strong quarter of record product revenue led by the continued momentum of the Sephience launch, putting us firmly on track to achieve our cash flow breakeven milestone this year.

10InnovAge Holding Corp.HealthcareMay 5, 2026-$0.22↑ Raised$0.06-467%-0.6%

We delivered a solid third quarter, reflecting continued improvement in operating execution and financial performance.

11Liquidia CorporationHealthcareNov 10, 2026-$2.64$0.96-375%+7.4%
Dr. Roger Jeffs, Chief Executive Officer

Five quarters after launch, YUTREPIA has rapidly established a preferred product profile because physicians value the control and flexibility it gives them over each patient's therapy.

12Hims & Hers Health, Inc.HealthcareNov 9, 2026-$0.14~ Mixed$0.06-349%-16.6%
Andrew Dudum, co-founder and CEO

In healthcare, whoever owns the customer relationship wins, and that's exactly what we're building toward at Hims & Hers. Today, customers want real choice, real value, and a care team that knows them.

13Innoviva, Inc.HealthcareNov 4, 2026-$1.03— Maintained$0.52-300%-8.1%
Pavel Raifeld, Chief Executive Officer

IST delivered another quarter of excellent growth, with U.S. net product sales increasing 45% year-over-year to $43.3 million, keeping us on track to achieve our 2026 guidance of at least $150 million in U.S. net product sales.

14Nanobiotix S.A.HealthcareMar 31, 2026-$0.46$0.30-251%+11.4%
15BioMarin Pharmaceutical Inc.HealthcareFeb 23, 2026-$0.24$0.17-242%-2.3%
16STAAR Surgical CompanyHealthcareMar 3, 2026-$0.20$0.18-211%+0.9%
17Brookdale Senior Living Inc.HealthcareMay 6, 2026-$0.03$0.03-200%-3.4%
18Cronos Group Inc.HealthcareFeb 26, 2026-$0.00$0.01-147%-3.6%
19Azenta, Inc.HealthcareMay 6, 2026-$0.04↓ Lowered$0.10-140%-24.5%

Our second quarter results fell short of our expectations, reflecting both execution gaps and a more cautious demand environment, particularly in North America.

20Caris Life Sciences, Inc.HealthcareAug 5, 2026-$0.00↑ Raised$0.01-139%+24.2%
David Dean Halbert, Founder, Chairman and CEO

This was a record quarter, with approximately 59,200 clinical cases, up more than 12% sequentially, reflecting sustained demand and the payoff from investments in our commercial engine.

21Telix Pharmaceuticals LimitedHealthcareFeb 19, 2026-$0.01$0.03-135%+20.0%
22UroGen Pharma Ltd.HealthcareNov 4, 2026-$0.03↓ Lowered$0.11-128%-25.2%
Liz Barrett, President and Chief Executive Officer

We delivered another strong quarter of execution, with ZUSDURI continuing to scale as growing repeat utilization, expanding community adoption, and broader physician engagement reinforce our confidence in the long-term commercial opportunity.

23Takeda Pharmaceutical Company LimitedHealthcareMay 13, 2026-$0.05$0.21-123%+1.3%
24Sarepta Therapeutics, Inc.HealthcareAug 5, 2026-$0.05$0.22-123%+2.4%
25Halozyme Therapeutics, Inc.HealthcareFeb 17, 2026-$0.24$2.15-111%-7.8%
AAPG logo1AAPGAscentage Pharma Group InternationalAug 20, 2026
Mkt Cap$1.2B
EPS Act.-$1.28
EPS Est.$0.02
Surprise-7850%
Reaction-5.7%
SectorHealthcare
MDGL logo2MDGLMadrigal Pharmaceuticals, Inc.Feb 19, 2026
Mkt Cap$9.2B
EPS Act.-$2.57
EPS Est.$0.04
Surprise-6525%
Reaction-11.5%
SectorHealthcare
BCRX logo3BCRXBioCryst Pharmaceuticals, Inc.May 6, 2026
Mkt Cap$1.9B
EPS Act.-$2.98
EPS Est.$0.06
Surprise-5067%
Reaction-1.4%
SectorHealthcare
HIMS logo4HIMSHims & Hers Health, Inc.May 11, 2026
Mkt Cap$3.8B
EPS Act.-$0.40
EPS Est.$0.03
Surprise-1675%
Reaction-11.5%
SectorHealthcare

2026 is a defining year for Hims & Hers. We're not just growing, we're pulling away from the field on our path to becoming the world's largest consumer health platform.

XERS logo5XERSXeris Biopharma Holdings, Inc.Aug 6, 2026
Mkt Cap$2.9B
EPS Act.-$0.18
EPS Est.$0.01
Surprise-1588%
Reaction-2.2%
SectorHealthcare
MOH logo6MOHMolina Healthcare, Inc.Feb 5, 2026
Mkt Cap$10.8B
EPS Act.-$2.75
EPS Est.$0.43
Surprise-740%
Reaction-26.0%
SectorHealthcare
MIRM logo7MIRMMirum Pharmaceuticals, Inc.Feb 25, 2026
Mkt Cap$5.6B
EPS Act.-$0.11
EPS Est.$0.02
Surprise-650%
Reaction-14.2%
SectorHealthcare
AHCO logo8AHCOAdaptHealth Corp.May 5, 2026
Mkt Cap$1.0B
EPS Act.-$0.06
EPS Est.$0.01
Surprise-580%
Reaction-12.4%
SectorHealthcare

The opening months of 2026 have set the stage for what will be a defining year for AdaptHealth. We completed the largest de novo expansion in the history of the home medical equipment industry, delivering revenue well ahead of our first quarter guidance.

PTCT logo9PTCTPTC Therapeutics, Inc.Oct 29, 2026
Mkt Cap$5.0B
EPS Act.-$0.62
EPS Est.$0.14
Surprise-532%
Reaction-7.0%
SectorHealthcare
Matthew B. Klein, M.D., Chief Executive Officer

We delivered another strong quarter of record product revenue led by the continued momentum of the Sephience launch, putting us firmly on track to achieve our cash flow breakeven milestone this year.

INNV logo10INNVInnovAge Holding Corp.May 5, 2026
Mkt Cap$1.2B
EPS Act.-$0.22
EPS Est.$0.06
Surprise-467%
Reaction-0.6%
SectorHealthcare

We delivered a solid third quarter, reflecting continued improvement in operating execution and financial performance.

LQDA logo11LQDALiquidia CorporationNov 10, 2026
Mkt Cap$5.0B
EPS Act.-$2.64
EPS Est.$0.96
Surprise-375%
Reaction+7.4%
SectorHealthcare
Dr. Roger Jeffs, Chief Executive Officer

Five quarters after launch, YUTREPIA has rapidly established a preferred product profile because physicians value the control and flexibility it gives them over each patient's therapy.

HIMS logo12HIMSHims & Hers Health, Inc.Nov 9, 2026
Mkt Cap$3.8B
EPS Act.-$0.14
EPS Est.$0.06
Surprise-349%
Reaction-16.6%
SectorHealthcare
Andrew Dudum, co-founder and CEO

In healthcare, whoever owns the customer relationship wins, and that's exactly what we're building toward at Hims & Hers. Today, customers want real choice, real value, and a care team that knows them.

INVA logo13INVAInnoviva, Inc.Nov 4, 2026
Mkt Cap$1.4B
EPS Act.-$1.03
EPS Est.$0.52
Surprise-300%
Reaction-8.1%
SectorHealthcare
Pavel Raifeld, Chief Executive Officer

IST delivered another quarter of excellent growth, with U.S. net product sales increasing 45% year-over-year to $43.3 million, keeping us on track to achieve our 2026 guidance of at least $150 million in U.S. net product sales.

NBTX logo14NBTXNanobiotix S.A.Mar 31, 2026
Mkt Cap$1.4B
EPS Act.-$0.46
EPS Est.$0.30
Surprise-251%
Reaction+11.4%
SectorHealthcare
BMRN logo15BMRNBioMarin Pharmaceutical Inc.Feb 23, 2026
Mkt Cap$11.9B
EPS Act.-$0.24
EPS Est.$0.17
Surprise-242%
Reaction-2.3%
SectorHealthcare
STAA logo16STAASTAAR Surgical CompanyMar 3, 2026
Mkt Cap$1.3B
EPS Act.-$0.20
EPS Est.$0.18
Surprise-211%
Reaction+0.9%
SectorHealthcare
BKD logo17BKDBrookdale Senior Living Inc.May 6, 2026
Mkt Cap$2.1B
EPS Act.-$0.03
EPS Est.$0.03
Surprise-200%
Reaction-3.4%
SectorHealthcare
CRON logo18CRONCronos Group Inc.Feb 26, 2026
Mkt Cap$1.2B
EPS Act.-$0.00
EPS Est.$0.01
Surprise-147%
Reaction-3.6%
SectorHealthcare
AZTA logo19AZTAAzenta, Inc.May 6, 2026
Mkt Cap$2.2B
EPS Act.-$0.04
EPS Est.$0.10
Surprise-140%
Reaction-24.5%
SectorHealthcare

Our second quarter results fell short of our expectations, reflecting both execution gaps and a more cautious demand environment, particularly in North America.

CAI logo20CAICaris Life Sciences, Inc.Aug 5, 2026
Mkt Cap$5.5B
EPS Act.-$0.00
EPS Est.$0.01
Surprise-139%
Reaction+24.2%
SectorHealthcare
David Dean Halbert, Founder, Chairman and CEO

This was a record quarter, with approximately 59,200 clinical cases, up more than 12% sequentially, reflecting sustained demand and the payoff from investments in our commercial engine.

TLX logo21TLXTelix Pharmaceuticals LimitedFeb 19, 2026
Mkt Cap$3.0B
EPS Act.-$0.01
EPS Est.$0.03
Surprise-135%
Reaction+20.0%
SectorHealthcare
URGN logo22URGNUroGen Pharma Ltd.Nov 4, 2026
Mkt Cap$1.5B
EPS Act.-$0.03
EPS Est.$0.11
Surprise-128%
Reaction-25.2%
SectorHealthcare
Liz Barrett, President and Chief Executive Officer

We delivered another strong quarter of execution, with ZUSDURI continuing to scale as growing repeat utilization, expanding community adoption, and broader physician engagement reinforce our confidence in the long-term commercial opportunity.

TAK logo23TAKTakeda Pharmaceutical Company LimitedMay 13, 2026
Mkt Cap$67.7B
EPS Act.-$0.05
EPS Est.$0.21
Surprise-123%
Reaction+1.3%
SectorHealthcare
SRPT logo24SRPTSarepta Therapeutics, Inc.Aug 5, 2026
Mkt Cap$1.5B
EPS Act.-$0.05
EPS Est.$0.22
Surprise-123%
Reaction+2.4%
SectorHealthcare
HALO logo25HALOHalozyme Therapeutics, Inc.Feb 17, 2026
Mkt Cap$11.4B
EPS Act.-$0.24
EPS Est.$2.15
Surprise-111%
Reaction-7.8%
SectorHealthcare